<DOC>
	<DOCNO>NCT02402686</DOCNO>
	<brief_summary>The aim non-interventional study Hungarian patient gather real life data efficacy safety tocilizumab subcutaneous ( SC ) monotherapy rheumatoid arthritis ass data pattern usage tocilizumab monotherapy rheumatoid arthritis ( RA ) disease management .</brief_summary>
	<brief_title>Non-Interventional Study Tocilizumab Subcutaneous Monotherapy Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>At least 18 year age Moderate severe RA accord 2010 American College Rheumatology ( ACR ) European League Against Rheumatism ( EULAR ) joint criterion Treatment tocilizumab SC monotherapy 8 week prior enrollment , prescriptive authority physician make decision commence tocilizumab accordance local label Methotrexate intolerance , inadequate response prior diseasemodifying antirheumatic drug ( DMARDs ) tumor necrosis factor ( TNF ) inhibitor continue methotrexate treatment deem inappropriate Treatment tocilizumab 8 week prior enrollment Failure meet local tocilizumab label indication criterion Treatment investigational agent within 4 week begin tocilizumab SC monotherapy Last methotrexate dose within 1 week begin tocilizumab SC monotherapy History autoimmune joint inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>